Supplemental Material for the manuscript titled "Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hid
Interleukin (IL)-17A is a key driver of inflammation and the principal target of anti-IL-17 therapeutic monoclonal antibodies. IL-17A, and its structurally similar family member IL-17F, have been show
Objective This study aimed to identify changes in the clinical presentation and treatment patterns of myasthenia gravis (MG) in Japan by comparing data from nationwide epidemiological surveys conducte
